|
Published by: Datamonitor
Published: Aug. 29, 2002 - 36 Pages
Table of Contents
Overview
Introduction
The XIV International AIDS Conference is the largest HIV-specific conference, bringing together the world’s foremost and imminent physicians, scientists and thought leaders. Both clinical and commercial data presented at the conference provides an extremely well rounded current knowledge of the latest breakthroughs in the HIV sector. This brief provides the reader with a concise and accurate analysis of the data presented at the conference, and the views of leading physicians globally.
Scope
The brief describes the main clinical trial data presented and analyzes the consequent market impacts of specific trial data
Key clinical trial data are presented for late stage HIV products, alongside analysis relating to their commercial prospects once launched
Report Highlights
The HIV market should experience a steady increase in patients entering the treatment-experienced pool in the next two to three years.
Reasons to Purchase
Clear analysis of the relevance and implications of clinical trial results presented at HIV's most important annual conference. Based on clinical trial data presented at the conference, the brief provides actionable marketing/drug positioning strategies for late phase products.
Scope
In-depth analysis of the NNRTI drug class, providing opinion leader input. Discussion of the key issue of when to start anti-retroviral therapy and the current viewpoints from a physician perspective
Report Highlights
The vast majority of pipeline drugs are being targeted towards this niche sector. Companies seeking to enter the market should center drug development strategies around this future epidemiological trend.
Reasons to Purchase
Insight from opinion leaders and practicing physicians
DRIVERS AND TRENDS
There are numerous products in the HIV pipeline globally. This is a result of an insufficient number of marketed HIV products, increasing prevalence of resistant viral strains and a predicted increase in the treatment-experienced pool relative to the treatment-naive patient pool. Companies will find it increasingly difficult to persuade physicians of a drug’s potential without markedly superior clinical trial data compared to other drugs. Not only does a pipeline drug need to be effective at reducing viral load, but it also has to confer tolerable side effect profiles, in order to achieve an improvement in maximum patient compliance. Given that vaccine development requires considerably longer periods of time to complete compared to drug development, manufacturers have to be sure of capturing physician confidence in their product.
PIPELINE DRUG ANALYSIS
An overview of the key HIV drugs in development. The anticipated launch of the fusion inhibitor, T-20 and latest clinical data. Coverage of pipeline drugs in other classes including protease inhibitors. Strategic analysis of the current vaccine pipeline.
CLINICAL COMPARISON OF THE NNRTIS
Review of BMS’ Sustiva and BI’s Viramune
Head-to-head clinical trials
Viramune Trials - Hepatotoxicity
Sustiva trials and CNS management
WHEN TO START ANTIRETROVIRAL THERAPY
A concise review of the guidelines and clinical trial data regarding initiation of HAART
DATASETS
Table 1: Efficacy of tipranavir/ritonavir in reducing viral load
Table 2: Pipeline drug usage in HIV therapy
Table 3: Geographical distribution of HIV vaccine strains
AbstractIntroduction: The XIV International AIDS Conference is the largest HIV-specific conference, bringing together the world's foremost and imminent physicians, scientists and thought leaders. Both clinical and commercial data presented at the conference provides an extremely well rounded current knowledge of the latest breakthroughs in the HIV sector. This Brief provides a concise and accurate analysis of the data presented at the conference, and the views of leading physicians globally. Scope of this Report: * Describes the main clinical trial data presented and analyzes the consequent market impacts of specific trial data * Key clinical trial data are presented for late stage HIV products, alongside analysis relating to their commercial prospects once launched * In-depth analysis of the NNRTI drug class, providing opinion leader input * Discussion of the key issue of when to start anti-retroviral therapy and the current viewpoints from a physician perspective. Report Highlights: The HIV market should experience a steady increase in patients entering the treatment-experienced pool in the next two to three years. The vast majority of pipeline drugs are being targeted towards this niche sector. Companies seeking to enter the market should center drug development strategies around this future epidemiological trend. Key Reasons to Buy this Report: * Clear analysis of the relevance and implications of clinical trial results presented at HIV's most important annual conference * Based on clinical trial data presented at the conference, the brief provides actionable marketing/drug positioning strategies for late phase products. * Insight from opinion leaders and practicing physicians.
Get Full Details About This Report >>
|
